APO-NABILONE 0.25 MG
NABILONE : 0.25 MG · DIN 02441497 · APOTEX INC
Health Canada status: APPROVED
What is APO-NABILONE?
APO-NABILONE 0.25 MG contains NABILONE : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02441497, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as approved, status dated 20-May-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02441497 |
|---|---|
| Brand name | APO-NABILONE |
| Generic / active ingredient | NABILONE : 0.25 MG |
| Manufacturer | APOTEX INC |
| Strength | 0.25 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA II) |
| ATC code | A04AD11 NABILONE |
| AHFS class | 56:22.92 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 20-May-2015 |
What can be used instead?
Other Canadian products sharing ATC code A04AD11 NABILONE. 9 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CESAMET | 0.25 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02312263 |
| CESAMET | 0.5 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02256193 |
| CESAMET | 1 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00548375 |
| PMS-NABILONE | 0.25 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02380897 |
| PMS-NABILONE | 0.5 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02380900 |
| PMS-NABILONE | 1.0 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02380919 |
| TEVA-NABILONE | 0.25 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02392925 |
| TEVA-NABILONE | 0.5 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02384884 |
| TEVA-NABILONE | 1.0 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02384892 |
| ACT NABILONE | 0.5 MG | CAPSULE | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02393581 |
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.